Biogen cov khoom lag luam tau nce lub hli dhau los tom qab FDA pom zoo lub tuam txhab biotech cov tshuaj, thawj cov tshuaj tau tshem tawm los ntawm Asmeskas cov tswj hwm kom txo qis kev txawj ntse hauv cov neeg nyob nrog Alzheimer's thiab thawj cov tshuaj tshiab rau tus kab mob ze li ob xyoo lawm.
Puas yog Biogen FDA pom zoo?
US Food and Drug Administration (FDA) tau pom zoo Biogen's monoclonal antibody aducanumab (Aduhelm) rau Lub Rau Hli 7 rau theem pib Alzheimer's kab mob- thawj txoj kev kho tshiab tau pom zoo rau cov kab mob neurogenerative hauv ze li ob xyoo lawm.
Puas aducanumab puas tau pom zoo los ntawm FDA?
On Lub Rau Hli 7, 2021, US Food and Drug Administration (FDA) tau pom zoo aducanumab (Aduhelm; Biogen Inc), thawj cov tshuaj tshiab rau kev kho mob Alzheimer hauv 2 xyoo caum.
tshuaj Biogen Alzheimer lub npe yog dab tsi?
FDA tau pom zoo cov tshuaj, hu ua Aduhelm thiab kev tshawb fawb hu ua aducanumab, lub lim tiam dhau los raws li cov pov thawj tias nws tuaj yeem txo cov quav hniav hauv hlwb.
Vim li cas aducanumab tau txais kev pom zoo?
Aducanumab tshem tawm cov kab mob ntawm cov protein hauv lub hlwb hu ua amyloid-β, uas qee cov kws tshawb fawb xav tias yog lub hauv paus ua rau Alzheimer's. Qhov kev xav no yog hu ua amyloid hypothesis. FDA pom zoo cov tshuaj nyob rau hauv lub hauv paus ntawm nws lub peev xwm los txo cov theem ntawm cov plaques nyob rau hauv lub hlwb.
